Skip to main content

Table 1 Life expectancy gains from cancer prevention strategies for BRCA1/2 positive women

From: Risk-reducing strategies for women carrying brca1/2 mutations with a focus on prophylactic surgery

Author and year Mutation type Type of prophylactic intervention
vs. surveillance
Life expectancy gain
(year)
Sonnenberg
et al 1993
BRCA 1/2 Tamoxifen for 5 years 1.6 to 2.2
Schrag
et al 1997
BRCA1/2 Bilateral Mastectomy
Bilateral oophorectomy
2.9 to 5.3
0.3 to 1.7
Grann
et al 1998
BRCA1/2 Bilateral oophorectomy
Bilateral mastectomy
Bilateral mastectomy and oophorectomy
0.4 to 2.6
2.8 to 3.4
3.3 to 6.0
Grann
et al 2000
BRCA1/2 Bilateral oophorectomy
Bilateral mastectomy
Bilateral oophorectomy and mastectomy
Chemoprevention with tamoxifen
Chemoprevention with raloxifene
0.9 ( 95% CI: 0.4-1.2)
3.4 (95% CI: 2.7-3.7)
4.3 (95% CI: 3.6-4.6 )
1.6 (95% CI: 1.0-2.1)
2.2 (95% CI: 1.3-2.8 )
Schrag
et al 2000
BRCA1/2 Tamoxifen for 5 years
Bilateral oophorectomy
Contra-lateral mastectomy
0.4 to 1.3
0.2 to 1.8
0.6 to 2.1
van Roosmalen
et al 2002
BRCA1/2 Bilateral mastectomy and oophorectomy
Breast screening and bilateral oophorectomy
Bilateral mastectomy with ovarian screening
High risk: 11.7. Medium risk 6.6
High risk: 9.5. Medium risk 5.3
High risk: 4.9. Medium risk 4.4
Armstrong
et al 2004
BRCA1/2 Bilateral oophorectomy
Bilateral mastectomy and prophylactic oophorectomy
3.34 to 4.65
5.49 to 7.63